Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.64 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.60 |
| ▸ | TOP2A | P11388 | 2/20 | 0.59 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12131079 | 0.96 | GSK3B (0.62) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1344616 | 0.91 | GSK3B (0.54) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1345033 | 0.90 | GSK3B (0.59) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL13581385 | 0.88 | GSK3B (0.59) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1343006 | 0.88 | GSK3B (0.65) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL3808002 | 0.87 | GSK3B (0.53) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL9689537 | 0.87 | GSK3B (0.68) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL1986275 | 0.87 | GSK3B (0.60) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL502617 | 0.87 | GSK3B (0.51) | GSK3BCACNA1FPOLBMAPK1CACNA1D | |
| SCHEMBL5783269 | 0.87 | GSK3B (0.51) | GSK3BCACNA1FPOLBMAPK1CACNA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065164-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED | 2005-03-24 | — | — | US | claimed |
| EP-1453824-A1 | NEW GENERATION TRIPLE-TARGETING, CHIRAL, BROAD-SPECTRUM ANTIMICROBIAL 7-SUBSTITUTED PIPERIDINO-QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, COMPOSITIONS AND USE AS MEDICAMENTS | Wockhardt Limited (IN) | 2004-09-08 | — | — | EP | claimed |
| US-20030216568-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments | WOCKHARDT LIMITED | 2003-11-20 | — | — | US | claimed |
| WO-2003050107-A1 | NEW GENERATION TRIPLE-TARGETING, CHIRAL, BROAD-SPECTRUM ANTIMICROBIAL 7-SUBSTITUTED PIPERIDINO-QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, COMPOSITIONS AND USE AS MEDICAMENTS | WOCKHARDT LIMITED (IN) | 2003-06-19 | — | — | WO | claimed |
| US-20030096812-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED | 2003-05-22 | — | — | US | claimed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-1666477-B1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-8106072-B2 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-5043450-A | Bactericides | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-27 | — | — | US | disclosed |
| EP-0226961-B1 | 5-AMINO AND 5-HYDROXY-6,8-DIFLUOROQUINOLONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1991-06-12 | — | — | EP | disclosed |
| US-4980470-A | 8-alkoxyquinolonecarboxylic acid and salts thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-12-25 | — | — | US | disclosed |
| US-4977154-A | 7-PIPERAZINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1990-12-11 | — | — | US | disclosed |
| EP-0342675-A2 | Novel quinolonecarboxylic acid derivatives | Chugai Seiyaku Kabushiki Kaisha (JP) | 1989-11-23 | — | — | EP | disclosed |
| US-4822801-A | 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivative as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-04-18 | — | — | US | disclosed |
| EP-0230295-A2 | 8-alkoxyquinolonecarboxylic acid and salts thereof excellent in the selective toxicity and process of preparing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-07-29 | — | — | EP | disclosed |
| EP-0226961-A1 | 5-Amino and 5-hydroxy-6,8-difluoroquinolones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096812-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | GSK3B 845/4885CACNA1F 4356/4885POLB 464/4885 |
| US-20050065164-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | GSK3B 845/4885CACNA1F 4356/4885POLB 464/4885 |
| US-20030216568-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | GSK3B 845/4885CACNA1F 4356/4885POLB 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.